PLK1 and renal carcinoma: As a result, the optimized complex exhibited a dose-dependent silencing capability of the polo-like kinase 1 (PLK-1) gene, a well-known proto-oncogene in the human renal carcinoma cell (OSRC-2) line, with no appreciable cytotoxicity [47].